News Innovation

Biotech advocates call on the feds to strengthen industry incentives

Advocates press for support from Ottawa to help the domestic biotech industry grow.

Elaine Campbell, left, interim president of Innovative Medicines Canada, says the long-serving Scientific Research and Experimental Development tax credit offers such negligible benefits for certain pharmaceutical companies they don't even bothering reporting in Canada to ascertain it. However, Andrew Casey, president of BIOTECanada, called it 'hugely important' for the biotechnology industry. Photographs courtesy of Innovative Medicines Canada and BIOTECanada


PUBLISHED : Wednesday, Sept. 7, 2016 12:00 AM

If you are already a subscriber

Subscribe to The Hill Times

Subscribe to the digital and/or print editions and get instant access to The Hill Times online.

Quick Purchase

Purchase Story Issue in electronic format (PDF) for $5.00.


More Stories In This Section


The Hill Times’ List of The Best Books in 2016


PBO again at odds with feds over budget details


All you need to know about marijuana legalization in Canada


People are better haters than forgivers


Spouses of Canadians to get permanent residency immediately: McCallum